contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


arcticzymes-technologies-asa-flagging-av-fullmakter-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.

MFN – 27 Jan 22              ArcticZymes Technologies: AZT: ArcticZymes Technologies Q4 2021 Res...    Tromsø, Norway, 27[th] January 2022 - ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.5 million (22.1) and an EBITDA of NOK 20.8 million (6.8) for the fourth quarter of 2021. Highligh...

Highlights from Q2 2021 · ArcticZymes Technologies (AZT) had Q2 sales of NOK 21.4 million - a  reduction of 36% (Q2 2020: NOK 33.4 million)  · Coronavirus-related sales are estimated at NOK 4.5 million in Q2 2021 (NOK  11.0 million in Q2 2020)  · Gross profit reduced to NOK 21.6 million as a result of lower sales (Q2  2020: NOK 33.0 million)  · AZT generated a positive EBITDA of NOK 6.0 million (Q2 2020: NOK 22.5  million)  · Cash-flow for Q2 was positive NOK 13.6 million (Q2 2020: NOK 20.4 million)  giving a cash balance of NOK 177.0 million (Q2 2020: NOK 56.1 million)  · Launched SAN HQ 2.0 at the end of the quarter  · Increased ownership in ArcticZymes AS from 96% to 100% by contribution in  kind

I’ve been following it, maybe a little too much.  100x San-HQ production capacity at the end of the last quarter. San 2.0 launched, with sales starting at the end of Q3, enabling a broader customer base. Lab-a-porter new distributor. New MDx customer. Virus X report completed - behind paywall. Arctic products starting to appear on Chinese websites. COVID-19 testing has not decreased. Two large cGMP auditors mentioned in the last quarter. Institutional ownership has increased. Reithera’s funding issues complicate and delay vaccine approval. Fortunately, those who have received two vaccine doses have been granted a green pass with a special permit. Speculation that Mexico will be involved in the next phase. There has been speculation about another COVID-19 vaccine manufacturer, but the name has not been released (Sanofi has appeared in Norwegian forums, speculation). Goal to add to the portfolio within 2-3 years. Personal suspicion is that the company will also start to attract potential buyers. Global enzyme market growth expected to grow by 9.4% by 2027 (CAGR), earlier forecast 7%. Pareto weakened its recommendation from 135 NOK to 133 NOK. Has the COVID-19 situation complicated sales or new agreements? Cyclicality of orders?  Sources:                  arcticzymes.com              ArcticZymes Technologies | The Enzyme Experts    Leading enzymes for biomanufacturing and diagnostics, brought to you by the inventors of COD UNG and salt-active nucleases.                            https://lab-a-porter.com/2021/06/novel-enzymes-from-the-arctic/           Our World in Data              Total COVID-19 tests    Comparisons across countries are affected by differences in testing policies and reporting methods.                             Generally, people have rather modest expectations, and systematically downplay/underestimate COVID-19 revenues. Good quarterly results have come from customers and similar companies.  In this company’s case, too, trust your own research and don’t listen to what others say.

Marketscreener shows an estimate of 30 MNOK revenue and 14 MNOK EBIT. This is based on one analyst’s forecast, which must mean Pareto, as they are the only analyst firm to have provided a target price.

Q2 report coming next Thursday. Has anyone (@SuperB) been following the news recently, what are the expectations?

hegnarmedia.auth.zephr.com – 3 May 21              Meglerhus tror kursfesten fortsetter    Pareto Securities forventer videre kursoppgang i ArcticZymes Technologies.                             Paretol (Paretol) this morning gave a target price of 135 for the AstraZeneca (AZT) share

Reithera – 26 Apr 21              ReiThera Completes Enrolment of Subjects in the Phase 2 Part of the Phase 2/3...    ROME, Italy, April 26th, 2021 – ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies, announces that it has completed the...         Est. reading time: 3 minutes                               Arcticzymes supplies SAN salt nuclease (SAN-suola nukleaasia) to Reithera for the vaccine.

ArcticZymes Technologies

Styrets leder, Marie Roskrow har idag mottatt fullmakter uten stemmeinstruks for å representere inntil 4.402.536 aksjer på den ordinære generalforsamlingen 23 juni 2022. Tilsammen representerer...

<pre>Styrets leder,&nbsp;Marie Roskrow&nbsp;har idag&nbsp;mottatt fullmakter uten stemmeinstruks for å representere inntil&nbsp;4.402.536 aksjer på den ordinære generalforsamlingen 23 juni 2022. Tilsammen representerer disse fullmaktene 8,74% av aksjene i selskapet på denne generalforsamlingen. For ytterligere informasjon: Børge Sørvoll CFO +47 952 90187 borge.sorvoll@arcticzymes.com </pre>